Loading…
Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis
The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of amino...
Saved in:
Published in: | The Journal of infectious diseases 1984-02, Vol.149 (2), p.257-263 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33 |
---|---|
cites | |
container_end_page | 263 |
container_issue | 2 |
container_start_page | 257 |
container_title | The Journal of infectious diseases |
container_volume | 149 |
creator | Tablan, Ofelia C. Reyes, Milagros P. Rintelmann, William F. Lerner, A. Martin |
description | The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at < 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin. |
doi_str_mv | 10.1093/infdis/149.2.257 |
format | article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_13834826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30109716</jstor_id><sourcerecordid>30109716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33</originalsourceid><addsrcrecordid>eNpFkM1v0zAYhy0EGmVw54KUA-JEOjt24_g4jbGCJphQEIiL9cYfq0did3YCy3-PS0uRLFnW7-N9_SD0kuAlwYKeOW-1S2eEiWW1rFb8EVqQFeVlXRP6GC0wrqqSNEI8Rc9SusMYM1rzE3RSs4oIxhbo1xfjoS_A6-J80m4McS7a8OCUG-ci2GLtbjflu5DM2-Imhj74W6OLdmMibOfitxs3xZXxIww54P-2tKGLMMy7Zz43yUw6DMFDKi69DgpiHuLSc_TEQp_Mi8N9ir6-v2wv1uX156sPF-fXpWKEjaUwApSyHTZYMdE1woCt858oCOAVM4wToZnGhqlO8w6YhVVlaacIgwZbSk_Rm33vNob7yaRRDi4p0_fgTZiSJLShrKnqbMR7o4ohpWis3EY3QJwlwXKHWu5Ry4xaVjKjzpFXh-6pG4w-Bg5ss_76oENS0NsIXuWCfzZR10Jw8r_mLmX6R5niPJWT3WblXndpNA9HHeJPWXPKV3L9_Yds2bc1EfST_Ej_AGV_oxk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>13834826</pqid></control><display><type>article</type><title>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</title><source>Oxford University Press Archive</source><source>JSTOR</source><creator>Tablan, Ofelia C. ; Reyes, Milagros P. ; Rintelmann, William F. ; Lerner, A. Martin</creator><creatorcontrib>Tablan, Ofelia C. ; Reyes, Milagros P. ; Rintelmann, William F. ; Lerner, A. Martin</creatorcontrib><description>The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at < 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/149.2.257</identifier><identifier>PMID: 6421944</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Administered dose ; Adult ; Aminoglycosides ; Antibiotics ; Auditory perception ; Auditory Threshold ; Biological and medical sciences ; Creatinine - blood ; Dosage ; Drug toxicity and drugs side effects treatment ; Endocarditis ; Endocarditis, Bacterial - drug therapy ; Female ; Gentamicins - administration & dosage ; Gentamicins - adverse effects ; Hearing loss ; Hearing Loss - chemically induced ; Hearing Loss, Bilateral - chemically induced ; Humans ; Infections ; Kidney Diseases - blood ; Kidney Diseases - chemically induced ; Male ; Medical sciences ; Nephrotoxicity ; Pharmacology. Drug treatments ; Pseudomonas ; Pseudomonas aeruginosa ; Pseudomonas Infections - drug therapy ; Tobramycin - administration & dosage ; Tobramycin - adverse effects ; Toxicity: urogenital system</subject><ispartof>The Journal of infectious diseases, 1984-02, Vol.149 (2), p.257-263</ispartof><rights>Copyright 1984 The University of Chicago</rights><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30109716$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30109716$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,58219,58452</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9669971$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6421944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tablan, Ofelia C.</creatorcontrib><creatorcontrib>Reyes, Milagros P.</creatorcontrib><creatorcontrib>Rintelmann, William F.</creatorcontrib><creatorcontrib>Lerner, A. Martin</creatorcontrib><title>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at < 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.</description><subject>Administered dose</subject><subject>Adult</subject><subject>Aminoglycosides</subject><subject>Antibiotics</subject><subject>Auditory perception</subject><subject>Auditory Threshold</subject><subject>Biological and medical sciences</subject><subject>Creatinine - blood</subject><subject>Dosage</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Endocarditis</subject><subject>Endocarditis, Bacterial - drug therapy</subject><subject>Female</subject><subject>Gentamicins - administration & dosage</subject><subject>Gentamicins - adverse effects</subject><subject>Hearing loss</subject><subject>Hearing Loss - chemically induced</subject><subject>Hearing Loss, Bilateral - chemically induced</subject><subject>Humans</subject><subject>Infections</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - chemically induced</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrotoxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Tobramycin - administration & dosage</subject><subject>Tobramycin - adverse effects</subject><subject>Toxicity: urogenital system</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><recordid>eNpFkM1v0zAYhy0EGmVw54KUA-JEOjt24_g4jbGCJphQEIiL9cYfq0did3YCy3-PS0uRLFnW7-N9_SD0kuAlwYKeOW-1S2eEiWW1rFb8EVqQFeVlXRP6GC0wrqqSNEI8Rc9SusMYM1rzE3RSs4oIxhbo1xfjoS_A6-J80m4McS7a8OCUG-ci2GLtbjflu5DM2-Imhj74W6OLdmMibOfitxs3xZXxIww54P-2tKGLMMy7Zz43yUw6DMFDKi69DgpiHuLSc_TEQp_Mi8N9ir6-v2wv1uX156sPF-fXpWKEjaUwApSyHTZYMdE1woCt858oCOAVM4wToZnGhqlO8w6YhVVlaacIgwZbSk_Rm33vNob7yaRRDi4p0_fgTZiSJLShrKnqbMR7o4ohpWis3EY3QJwlwXKHWu5Ry4xaVjKjzpFXh-6pG4w-Bg5ss_76oENS0NsIXuWCfzZR10Jw8r_mLmX6R5niPJWT3WblXndpNA9HHeJPWXPKV3L9_Yds2bc1EfST_Ej_AGV_oxk</recordid><startdate>198402</startdate><enddate>198402</enddate><creator>Tablan, Ofelia C.</creator><creator>Reyes, Milagros P.</creator><creator>Rintelmann, William F.</creator><creator>Lerner, A. Martin</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>198402</creationdate><title>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</title><author>Tablan, Ofelia C. ; Reyes, Milagros P. ; Rintelmann, William F. ; Lerner, A. Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Administered dose</topic><topic>Adult</topic><topic>Aminoglycosides</topic><topic>Antibiotics</topic><topic>Auditory perception</topic><topic>Auditory Threshold</topic><topic>Biological and medical sciences</topic><topic>Creatinine - blood</topic><topic>Dosage</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Endocarditis</topic><topic>Endocarditis, Bacterial - drug therapy</topic><topic>Female</topic><topic>Gentamicins - administration & dosage</topic><topic>Gentamicins - adverse effects</topic><topic>Hearing loss</topic><topic>Hearing Loss - chemically induced</topic><topic>Hearing Loss, Bilateral - chemically induced</topic><topic>Humans</topic><topic>Infections</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - chemically induced</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrotoxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Tobramycin - administration & dosage</topic><topic>Tobramycin - adverse effects</topic><topic>Toxicity: urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tablan, Ofelia C.</creatorcontrib><creatorcontrib>Reyes, Milagros P.</creatorcontrib><creatorcontrib>Rintelmann, William F.</creatorcontrib><creatorcontrib>Lerner, A. Martin</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tablan, Ofelia C.</au><au>Reyes, Milagros P.</au><au>Rintelmann, William F.</au><au>Lerner, A. Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1984-02</date><risdate>1984</risdate><volume>149</volume><issue>2</issue><spage>257</spage><epage>263</epage><pages>257-263</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>The nephrotoxicity and auditory toxicity of high-dose (mean, 28.6 g) and prolonged (mean, 61.6 days) courses of gentamicin and tobramycin were monitored in 15 patients receiving 17 courses of treatment for pseudomonas endocarditis. Doses were adjusted in a manner that maintained peak levels of aminoglycoside in serum at 12–15 µg/ml and trough levels at < 2 µg/ml. Drug-related renal dysfunction and auditory toxicity occurred in 63% and 44%, respectively, of gentamicin-treated patients and in 43% and 25%, respectively, of tobramycin-treated patients. Mean maximal rises (± SEM).in serum creatinine levels were 0.8 (± 0.4) mg/dl in the group given gentamicin and 1.6 (± 0.7) mg/dl in the group given tobramycin. Mean maximal decreases in pure-tone hearing threshold levels were greater in gentamicin-treated patients (58.3 dB) than in those given tobramycin (22.5 dB). Both forms of toxicity appeared earlier and at a smaller dose with gentamicin than with tobramycin.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>6421944</pmid><doi>10.1093/infdis/149.2.257</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1899 |
ispartof | The Journal of infectious diseases, 1984-02, Vol.149 (2), p.257-263 |
issn | 0022-1899 1537-6613 |
language | eng |
recordid | cdi_proquest_miscellaneous_13834826 |
source | Oxford University Press Archive; JSTOR |
subjects | Administered dose Adult Aminoglycosides Antibiotics Auditory perception Auditory Threshold Biological and medical sciences Creatinine - blood Dosage Drug toxicity and drugs side effects treatment Endocarditis Endocarditis, Bacterial - drug therapy Female Gentamicins - administration & dosage Gentamicins - adverse effects Hearing loss Hearing Loss - chemically induced Hearing Loss, Bilateral - chemically induced Humans Infections Kidney Diseases - blood Kidney Diseases - chemically induced Male Medical sciences Nephrotoxicity Pharmacology. Drug treatments Pseudomonas Pseudomonas aeruginosa Pseudomonas Infections - drug therapy Tobramycin - administration & dosage Tobramycin - adverse effects Toxicity: urogenital system |
title | Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas Endocarditis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T13%3A13%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renal%20and%20Auditory%20Toxicity%20of%20High-Dose,%20Prolonged%20Therapy%20with%20Gentamicin%20and%20Tobramycin%20in%20Pseudomonas%20Endocarditis&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Tablan,%20Ofelia%20C.&rft.date=1984-02&rft.volume=149&rft.issue=2&rft.spage=257&rft.epage=263&rft.pages=257-263&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/149.2.257&rft_dat=%3Cjstor_proqu%3E30109716%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-9e9accfb0e0c49b89eaf60223a9a724e4719d4d0e4cbd7ba4fa52f3bc14a80f33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=13834826&rft_id=info:pmid/6421944&rft_jstor_id=30109716&rfr_iscdi=true |